Modern view on the effectiveness and safety of non-steroidal anti-inflammatory drugs

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Issues of the effectiveness and safety of drugs remain relevant and controversial. The benefits and risks of drug therapy are two facets of one whole, called pharmacotherapy, which can have undesirable side and even negatively outweigh the benefits. The effectiveness and safety of drugs must be studied comprehensively because new effects of drugs may be discovered and new mechanisms for unregistered indications may be revealed. Moreover, a deep understanding of adverse drug reactions will allow for the accurate prescription of drugs and proper medical supervision of therapy. Nonsteroidal anti-inflammatory drugs are over-the-counter drugs perceived by patients as safe and do not require a doctor’s prescription, which can cause dangerous drug reactions, particularly when used uncontrollably. The review presents literature data from studies on the effectiveness of nonsteroidal anti-inflammatory drugs and current data on new therapeutic effects of individual drugs, risks of adverse reactions, their mechanisms, and treatment methods.

Full Text

Restricted Access

About the authors

Liliya L. Shamal

Kuban State Medical University

Author for correspondence.
Email: levonna@list.ru
ORCID iD: 0009-0008-7694-1532
SPIN-code: 5074-9529

MD, Cand. Sci. (Pharmacy)

Russian Federation, Krasnodar

Olga V. Shelemekh

Rostov State University

Email: lioli777@yandex.ru
ORCID iD: 0000-0003-3488-9971
Russian Federation, Rostov-on-Don

Roman A. Murashko

Kuban State Medical University

Email: ramurashko@rambler.ru
ORCID iD: 0000-0001-8873-8461
SPIN-code: 8484-2695

MD, Dr. Sci. (Medicine)

Russian Federation, Krasnodar

Tereza R. Glechyan

Kuban State Medical University

Email: t_g91@mail.ru
ORCID iD: 0009-0002-4983-2433
SPIN-code: 2138-2536
Russian Federation, Krasnodar

Pavel A. Galenko-Yaroshevskii

Kuban State Medical University

Email: galenko.yarochevsky@gmail.com
ORCID iD: 0000-0003-3190-1437
SPIN-code: 1575-6129
Russian Federation, Krasnodar

References

  1. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29. EDN: PCPKRP doi: 10.14412/1995-4484-2018-1-29
  2. Cooney MF. Pain management in children: NSAID Use in the perioperative and emergency department settings. Pediatr Drugs. 2021;23:361–372. doi: 10.1007/s40272-021-00449-z
  3. Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Modern Rheumatology Journal. 2019;13(4):11–17. EDN: VFVQEE doi: 10.14412/1996-7012-2019-4-11-17
  4. Balabanova RM, Dubinina TV, Demina AV, Krichevskaya OA. The incidence of musculoskeletal diseases in the Russian Federation over 2015–2016. Rheumatology Science and Practice. 2018;56(1):15–21. EDN: XPLNLF doi: 10.14412/1995-4484-2018-15-21
  5. Nasonov EL. Russian clinical recommendations. Rheumatology. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)
  6. Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Rheumatology Science and Practice. 2016;54(3):247–265. EDN: WXHGNX doi: 10.14412/1995-4484-2016-247-265
  7. Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, et al. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anesthesiology. 2022;136:843–860. doi: 10.1097/ALN.0000000000004141
  8. Serebrennikova SN, Seminsky IZh, Guzovskaiia EV, Gutsol LO. Inflammation as a fundamental pathological process: lecture 2 (cellular component). Baikal Medical Journal. 2023;2(2):65–76. EDN: ALTEJQ doi: 10.57256/2949-0715-2023-2-65-76
  9. Karateev AE, Uspensky YuP, Pakhomova IG, Nasonov EL. A concise course of the history of NSAIDs. Rheumatology Science and Practice. 2012;50(3):101–116. EDN: PLWYPR doi: 10.14412/1995-4484-2012-718
  10. Wikipedia: [Electronic resource] URL: https://ru.wikipedia.org/wiki/%D0%9F%D1%80%D0%BE%D1%81%D1%82%D0%B0%D0%B3%D0%BB%D0%B0%D0%BD%D0%B4%D0%B8%D0%BD%D1%8B (cited 01 Feb 2024)
  11. Godzenko AA, Godzenko MV. The role of nonsteroidal anti-inflammatory drugs in the treatment of spondylarthritis. Effective pharmacotherapy. 2019;15(23):6–10. EDN: RITULZ doi: 10.33978/2307-3586-2019-15-23-6-10
  12. Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. PNAS USA. 2019;116(13):6292–6297. doi: 10.1073/pnas.1804000116
  13. Karateev AE, Aleinikova TL. Eicosanoids and inflammation. Modern Rheumatology Journal. 2016;10(4):73–86. EDN: XEKFCP doi: 10.14412/1996-7012-2016-4-73-86
  14. Serhan CN, Levy BD. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657–2669. doi: 10.1172/JCI97943
  15. Wall T, Sherwin A, Ma D, Buggy DJ. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: A narrative review. Br J Anaesth. 2019;123(2):135–150. doi: 10.1016/j.bja.2019.04.062
  16. Ma W, Wang K, Du J, et al. Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer. Mol Med Rep. 2015;11(4):2999–3008. doi: 10.3892/mmr.2014.3003
  17. Kaufmann KB, Heinrich S, Staehle HF, et al. Perioperative cytokine profile during lung surgery predicts patients at risk for postoperative complications: A prospective, clinical study. PLoS One. 2018;13: e0199807. doi: 10.1371/journal.pone.0199807
  18. Leijte GP, Kiers D, van der Heijden W, et al. Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: A randomized placebo-controlled study. Crit Care Med. 2019;47(4):508–516. doi: 10.1097/CCM.0000000000003630
  19. Kiers D, van der Heijden WA, van Ede L, et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017;117(9):1798–1807. doi: 10.1160/th16-10-0799
  20. Trauer J, Muhi S, McBryde ES, et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: An individual patient data meta-analysis using propensity matching. Crit Care Med. 2017;45(11):1871–1879. doi: 10.1097/ccm.0000000000002654
  21. Eisen DP, Leder K, Woods RL, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): A randomised, double-blind, placebo-controlled primary prevention trial. Lancet Respir Med. 2021;9(2):186–195. doi: 10.1016/s2213-2600(20)30411-2
  22. Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone?: Meta-analyses of randomized trials. Anesthesiology. 2005;103:1296–1304. doi: 10.1097/00000542-200512000-00025
  23. Maund E, McDaid C, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: A systematic review. Br J Anaesth. 2011;106(3):292–297. doi: 10.1093/bja/aeq406
  24. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: Meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–1260. doi: 10.1097/00000542-200506000-00027
  25. Yang P-M, Liu Y-L, Lin Y-C, et al. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010;70(19):7699–7709. doi: 10.1158/0008-5472.can-10-1626
  26. Guo L, Gao J, Gao Y, et al. Aspirin reshapes acetylomes in inflammatory and cancer cells via CoA-Dependent and CoA-independent pathways. J Proteome Res. 2020;19(2):962–972. doi: 10.1021/acs.jproteome.9b00853
  27. Chen WY, Holmes MD. Role of aspirin in breast cancer survival. Curr Oncol Rep. 2017;19(7):48. doi: 10.1007/s11912-017-0605-6
  28. Takiuchi T, Blake EA, Matsuo K, et al. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148(1):222–232. doi: 10.1016/j.ygyno.2017.10.026
  29. Chen J, Shen P, Zhang X-C, et al. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther. 2014;36(8):1253–1263. doi: 10.1016/j.clinthera.2014.06.015
  30. Zhang X, Feng Y, Liu X, et al. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. J Cancer Res Clin Oncol. 2019;145(6):1387–1403. doi: 10.1007/s00432-019-02902-6
  31. Movahedi M, Bishop DT, Macrae F, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol. 2015;33(31):3591–3597. doi: 10.1200/jco.2014.58.9952
  32. Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. J Am Med Assoc Oncol. 2016;2(6):762–769. doi: 10.1001/jamaoncol.2015.6396
  33. Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. Br Med J. 2016;355:i6188. doi: 10.1136/bmj.i6188
  34. Lu Y, Liu L-L, Liu S-S, et al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J Transl Med. 2016;14:270. doi: 10.1186/s12967-016-1012-8
  35. Suzuki K, Gerelchuluun A, Hong Z, et al. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol. 2013;15(9):1186–1199. doi: 10.1093/neuonc/not062
  36. Yu C, Li W-B, Liu J-B, et al. Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer. Cancer Med. 2018;7(2):471–484. doi: 10.1002/cam4.1287
  37. Lu Y, Liu X-F, Liu T-R, et al. Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function. Biomed Pharmacother. 2016;84:1551–1557. doi: 10.1016/j.biopha.2016.11.026
  38. Zhao Q, Wang Z, Wang Z, et al. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett. 2016;12(4):2804–2810. doi: 10.3892/ol.2016.5017
  39. Han HY, Kim H, Jeong SH, et al. Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac J Cancer Prev. 2014;15(16):6939–6944. doi: 10.7314/apjcp.2014.15.16.6939
  40. Mazzanti R, Platini F, Bottini C, et al. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem Pharmacol. 2009;78:21–32. doi: 10.1016/j.bcp.2009.03.013
  41. Chu M, Wang T, Sun A, Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Exp Ther Med. 2018;16(1):370–376. doi: 10.3892/etm.2018.6191
  42. Catarro M, Serrano JL, Ramos SS, et al. Nimesulide analogues: From anti-inflammatory to antitumor agents. Bioorg Chem. 2019;88:102966. doi: 10.1016/j.bioorg.2019.102966
  43. D’Arcy Y, Mantyh P, Yaksh T, et al. Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. Postgrad Med. 2021;133(8):879–894. doi: 10.1080/00325481.2021.1949199
  44. Kalagova AV, Ailarova NR, Panagov ZG. NSAIDS-gastropathy in patients with rheumatoid arthritis. Bulletin of Science and Education. 2019;(1–1):97–100. EDN: YTIBBR
  45. Erdes ShF, Rumiantceva DG. Long-term use of non-steroidal anti-inflammatory drugs in the treatment of axial spondylitis. Farmatefa. 2019;26(13):24–29. EDN: HZAPMS doi: 10.18565/pharmateca.2019.13.24-29
  46. Sobolenko DD, Belykh VD, Belyi BU. The deadly influence of non-steroid anti-inflammatory medicines on the mucosa of the small intestinal: the relevance of the problem. Russian Military Medical Academy Reports. 2021;40(S1–1):165–168. EDN: WERMQO
  47. Hladkykh FV. Preventive and therapeutic strategies of pharmaco-correction gastropathy induced by nonsteroidal anti-inflammatory drugs. Reviews on Clinical Pharmacology and Drug Therapy. 2017;15(4):14–23. EDN: YLLSXK doi: 10.17816/RCF15414-23
  48. Andrews EB, Arellano FM, Avorn J, et al. Good pharmacoepidemiology practice (GPP). Moscow: Remedium; 2017. 36 p.
  49. Mufazalova NA, Valeeva LA, Davletshin RA, et al. Undesirable drug reactions. Drug interactions. Part I. Nonsteroidal anti-inflammatory drugs: Textbook. Ufa: FGBOU VO BGMU of the Ministry of Health of Russia; 2020. 195 p. doi: 10.17513/np.416 (In Russ.)
  50. Iskakov BS, Kulumbaeva AB, Yessirkepova GS. NSAID-induced gastropathy in rheumatology practice: current issues in diagnosis and treatment. Bulletin of the Kazakh National Medical University. 2018;(2):486–492. EDN: YWGGMH
  51. Horoshun MS, Lazareva AA. Prescribing of non-steroidal anti-inflammatory drugs: benefits and risks. University Therapeutic Journal. 2022;4(1):4–10. doi: 10.56871/3854.2022.69.43.001
  52. Maev IV, Osadchuk MA, Krylova YuS, et al. Motilin, vascular endothelial growth factor, and somatostatin expression in the gastric mucosa of patients with NSAID-gastropathy. Russian Journal of Evidence-Based Gastroenterology. 2022;11(4):2231. EDN: OWFHCO doi: 10.17116/dokgastro20221104122
  53. National clinical guidelines (summary) of association of rheumatologists of Russia, Russian gastroenterological association, Russian association for the study of pain “rational treatment by non-steroidal anti-inflammatory drugs”: the draft (data of the expert board meeting, Moscow, 01.04.2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):69–75. EDN: ZHQRYZ
  54. Lesnaya OA, Rusanova EI, Prokofieva EB, Freire Da Silva T. Rational use of NSAIDs according to clinical guidelines and data from recent studies. Difficult patient. 2019;17(10):31–34. EDN: FEWBVK doi: 10.24411/2074-1995-2019-10072
  55. Velts NYu, Zhuravleva EO, Bukatina TM, Kutekhova GV. Nonsteroidal anti-inflammatory drugs: problems of safe use. Safety and Risk of Pharmacotherapy. 2018;6(1):11–18. EDN: YTLADS doi: 10.30895/2312-7821-2018-6-1-11-18
  56. Kamchatnov PR, Chugunov AV, Chipova DT, Kazakov AYu. Nonsteroidal anti-inflammatory drugs and the risk of heart failure. RMJ. 2023;(2):88–95. EDN: JHGYGM
  57. Chichasova N.V. Current recommendations for the treatment of osteoarthritis. Consilium Medicum. 2016;18(2):124–133.
  58. Balabanova RM, Podryadnova MV. Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis. Modern Rheumatology Journal. 2014;8(4):86–89. EDN: TAKCPX doi: 10.14412/1996-7012-2014-4-86-89
  59. Dydykina IS, Nurbaieva KS, Kovalenko PS, et al. From knowing the mechanism of action to choosing a method for the prevention and treatment of osteoarthritis. RMJ. 2020;28(7):14–18. EDN: LMCZKJ
  60. Sсherbak SG, Makarenko SV, Shneider OV, et al. Regenerative Rehabilitation in Injuries of Tendons. Physical and rehabilitation medicine, medical rehabilitation. 2021;3(2):192–206. EDN: FGSGHR doi: 10.36425/rehab70760
  61. Scarabin P-Y, Oger E, Plu-Bureau G, EStrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogenreplacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–432. doi: 10.1016/S0140-6736(03)14066-4
  62. Rebrov AP. Pain, NSAIDs, and chronic kidney disease: a difficult relationship. South Russian Journal of Therapeutic Practice. 2022;3(2): 25–31. EDN: MSOHXN doi: 10.21886/2712-8156-2022-3-2-25-31
  63. Panevin TS, Voronina NV. Kidney damage in rheumatic diseases: new prospects for nephroprotection. Far East Medical Journal. 2022;(3):129–136. EDN: KQYMJW doi: 10.35177/1994-5191-2022-3-20
  64. Domingo C, Palomares O, Sandham DA, et al. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. Respir Res. 2018;19:189. doi: 10.1186/s12931-018-0893-x
  65. Pronina IV. Leukotrienes and a modern view of the use of their antagonists in the treatment of bronchial asthma. International Student Scientific Bulletin. 2020;(2):20. EDN: WVREKP
  66. Zharkih МА, Jablonsky SV, Mokronosova MA. Leukotrienes and antileukotriene drugs in allergic rhinitis. Pediatric pharmacology. 2009;6(5):20–29. EDN: KYLVET
  67. Kniazheskaya NP, Chuchalin AG. Current aspects of aspirin-induced bronchial asthma. Pulmonologiya. 1999;(2):91–94.
  68. Karateyev AYe, Zhuravlyova MV. Analysis of spontaneous reports provided by Russian physicians regarding adverse reactions occurring after administration of nimesulide: hepatotoxic complications occur very rarely. Effective pharmacotherapy. 2015;(2):4–12.
  69. Caiazzo E, Ialenti A, Cicala C. The relatively selective cyclooxygenase2 inhibitor nimesulide: What’s going on? Eur J Pharmacol. 2019;848:105–111. doi: 10.1016/j.ejphar.2019.01.044
  70. Yang Z, Ji W, Li M, et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am J Transl Res. 2019;11(9):6024–6031.
  71. Podobed VM. Zinc Сarnosin: a new formula of gastroprotection and making up zinc deficiency. Matters of certification and professional development. 2015;(2):17–20.
  72. Karkishchenko VN, Pomytkin IA, Karkishchenko NN. Peptide activators of sirtuin 1 (SIRT1) expression: a new class of anti-inflammatory drugs. Experimental and clinical pharmacology. 2023;86(11S):115. EDN: VVCMKY doi: 10.30906/ekf-2023-86s-69b (In Russ.)

Copyright (c) 2024 ECO-vector LLC

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies